PeptiDream Executive and Leadership Team

Patrick Reid, the Chief Executive Officer & President at PeptiDream, directs the company's overarching strategy and operational execution. Reid guides PeptiDream's mission to become a global leader in drug discovery, leveraging the proprietary Peptide Discovery Platform System (PDPS) to identify potent therapeutic candidates. This leadership involves fostering innovation and ensuring the efficient development of peptide-based, small molecule-based, or peptide-drug-conjugate-based therapeutics. Reid's focus remains on addressing critical unmet medical needs and improving patient outcomes worldwide. The Chief Executive Officer & President oversees all departments, ensuring alignment with the company's long-term vision and market objectives. By championing the PDPS technology, Patrick Reid drives the company's competitive advantage and its commitment to advancing healthcare solutions. This executive role is central to PeptiDream's global expansion and its pursuit of groundbreaking pharmaceutical advancements.

Kiichi Kubota, the President & Chief Executive Officer at PeptiDream, spearheads the company's strategic direction and executive leadership. Kubota's role involves driving the advancement of PeptiDream's proprietary Peptide Discovery Platform System (PDPS), a critical asset for generating diverse peptide libraries. This leadership ensures the efficient identification of highly potent and selective hit candidates for therapeutic development. Kubota focuses on establishing PeptiDream as a preeminent force in drug discovery and development, aiming to significantly improve the quality of life for patients globally. The President & Chief Executive Officer oversees strategic partnerships and resource allocation, ensuring the company's pipeline progresses effectively. By championing the PDPS platform, Kiichi Kubota reinforces PeptiDream's commitment to innovation and its mission to tackle significant unmet medical needs through novel therapeutic approaches.

Kiyofumi Kaneshiro, the Chief Financial Officer at PeptiDream, manages the company's financial operations and strategic fiscal planning. Kaneshiro oversees all aspects of financial reporting, budgeting, and investment strategies, ensuring the fiscal health and sustainability of PeptiDream's drug discovery and development initiatives. This executive role is crucial for supporting the efficient operation of the proprietary Peptide Discovery Platform System (PDPS) and the progression of therapeutic candidates through development pipelines. Kaneshiro's financial acumen guides resource allocation, enabling the company to pursue its mission of addressing unmet medical needs and enhancing patient quality of life. The Chief Financial Officer works closely with other executive leaders to align financial objectives with the company's ambitious growth targets and market expansion plans. Kiyofumi Kaneshiro's leadership ensures robust financial controls and strategic financial management, vital for PeptiDream's position as a leader in biopharmaceutical innovation.

Keiichi Masuya, the Chief Operating Officer at PeptiDream, directs the company's day-to-day operational activities and process optimization. Masuya ensures the seamless execution of research and development processes, particularly concerning the proprietary Peptide Discovery Platform System (PDPS), maximizing its efficiency in producing diverse peptide libraries. This leadership role is fundamental to the company's ability to identify and develop highly potent therapeutic candidates for unmet medical needs. Masuya oversees the integration of operational strategies with scientific advancements, driving the company's mission to improve patient quality of life worldwide. The Chief Operating Officer collaborates with other C-suite executives to streamline workflows, manage resources effectively, and support the progression of peptide-based, small molecule-based, and peptide-drug-conjugate-based therapeutics. Keiichi Masuya's operational oversight is critical for maintaining PeptiDream's competitive edge and its commitment to delivering innovative healthcare solutions.